New ABCC8 Mutations in Relapsing Neonatal Diabetes and Clinical Features

  1. Martine Vaxillaire1,
  2. Aurélie Dechaume1,
  3. Kanetee Busiah23,
  4. Hélène Cavé4,
  5. Sabrina Pereira4,
  6. Raphael Scharfmann25,
  7. Guiomar Perez de Nanclares6,
  8. Luis Castano6,
  9. Philippe Froguel17,
  10. Michel Polak235 and
  11. and the SUR1–Neonatal Diabetes Study Group*
  1. 1Centre National de la Recherche Scientifique, UMR8090, Institute of Biology, Pasteur Institute, Lille, France
  2. 2Faculty of Medicine, René Descartes Paris 5 University, Paris, France
  3. 3Department of Pediatric Endocrinology, Necker Enfants Malades Hospital, Paris, France
  4. 4Department of Genetic Biochemistry, Robert Debré Hospital, Paris, France
  5. 5INSERM, U845, Necker Enfants Malades Hospital, Paris, France
  6. 6Endocrinology and Diabetes Research Group, Hospital de Cruces, Barakaldo, Bizkaia, Spain
  7. 7Genomic Medicine, Hammersmith Hospital, Imperial College, London, U.K
  1. Address correspondence and reprint requests to Dr. Martine Vaxillaire, CNRS UMR8090 and Institute of Biology of Lille, Institut Pasteur, 1 rue du Professeur Calmette, BP 245, 59019 Lille, France. E-mail: martine.vaxillaire{at}good.ibl.fr

Abstract

Activating mutations in the ABCC8 gene that encodes the sulfonylurea receptor 1 (SUR1) regulatory subunit of the pancreatic islet ATP-sensitive K+ channel (KATP channel) cause both permanent and transient neonatal diabetes. Recently, we have described the novel mechanism where basal Mg-nucleotide–dependent stimulatory action of SUR1 on the Kir6.2 pore is increased. In our present study, we identified six new heterozygous ABCC8 mutations, mainly in patients presenting the transient form of neonatal diabetes (six of eight), with a median duration of initial insulin therapy of 17 months (range 0.5–38.0). Most of these mutations map to key functional domains of SUR1. Whereas Kir6.2 mutations are a common cause of permanent neonatal diabetes and in a few cases associate with the DEND (developmental delay, epilepsy, and neonatal diabetes) syndrome, SUR1 mutations are more frequent in transient (52%) compared with permanent (14%) neonatal diabetes cases screened for ABCC8 in our series. Although ketoacidosis is frequent at presentation, SUR1 mutations associate mainly with transient hyperglycemia, with possible recurrence later in life. One-half of the SUR1 neonatal diabetic patients presented with de novo mutations. In some familial cases, diabetes is not always present in the adult carriers of SUR1 mutations, supporting variability in their clinical expressivity that remains to be fully explained.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 27 March 2007. DOI: 10.2337/db06-1540.

  • Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db06-1540.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • *

    * A list of members of the SUR1–Neonatal Diabetes Study Group can be found in the appendix.

    • Accepted March 3, 2007.
    • Received November 3, 2006.
« Previous | Next Article »Table of Contents